 LONDON, Dec. 12, 2022 GLOBE NEWSWIRE -- Autolus Therapeutics plc Nasdaq: AUTL, a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announces the online publication of three posters with updates from three Phase 1 clinical trials to be presented at the American Society of Hematology ASH Annual Meeting, December 10-13, 2022. 